All In Biotech

Drug Trial Radar · NCT05508100

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

A Phase 1, Open-Label, Multicenter Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IO-108 as Monotherapy and in Combination With Anti-PD-1 Monoclonal Antibody in Adult Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Sep 9, 2022

Primary completion

Apr 30, 2024

Study completion Apr 30, 2024

Sponsor

Lead sponsor
Immune-Onc TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of IO-108 monotherapy and in combination with anti-PD-1 monoclonal antibody pembrolizumab or tislelizumab in adult patients with advanced solid tumors. The study will be conducted in 3 parts, including Part A IO-108 monotherapy dose confirmation; Part B IO-108 + anti-PD-1 dose confirmation, and Part C dose expansion.

Conditions

  • Advanced Solid Tumor

Interventions

  • IO-108Biological

    IO-108, intravenously, on Day 1 of each 21-day cycle.

  • IO-108 + pembrolizumabBiological

    IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.

  • IO-108 + tislelizumabBiological

    IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108Time frame: through study completion, an average of 2 years
  2. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108 in combination with pembrolizumab or tislelizumabTime frame: through study completion, an average of 2 years
  3. Preliminary anti-tumor activity of IO-108 in combination with pembrolizumab or tislelizumabTime frame: through study completion, an average of 2 years

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Fujian Medical University

    Fujian, Fuzhou, China

  • 1st affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • 4th Hospitla of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Lin Yi Cancer Hospital

    Linyi, Shandong, China

  • Shanghai Dong Fang Hospital

    Shanghai, Shanghai Municipality, China

  • 1st Affiliated Hospital of Xi'an Jiaotong University

    Xian, Shanxi, China

  • Sir RUN RUN SHAW HOSPITAL

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.